There are currently 31 active clinical trials seeking participants for Acute Kidney Injury research studies. The states with the highest number of trials for Acute Kidney Injury participants are California, Ontario, Texas and New York.
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
NCT04750616
Recruiting
A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Kaiser Permanente San Francisco Medical Center, San Francisco, California
Conditions: Ischemia Reperfusion Injury, Myocardial Injury, Acute Kidney Injury
Register for Updates
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
NCT06652100
Recruiting
The purpose of this research is to collect blood and urine from adult patients admitted to an intensive care unit. This is to assess the performance of the ProNephro AKI (NGAL) assay (lab test) as an aid to identify patients at risk for acute kidney injury.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/24/2025
Locations: The University of Alabama, Birmingham, Alabama +11 locations
Conditions: Acute Kidney Injury
Register for Updates
A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention
NCT04403633
Recruiting
The purpose of this study is to improve patient-centered care for acute kidney injury (AKI) in order to decrease the adverse health outcomes associated with this common condition.
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
02/03/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Acute Kidney Injury
Register for Updates
Biomarkers of AKI in Patients Receiving Daratumumab
NCT06549634
Recruiting
The goal of this prospective observational study is to understand changes in urinary and blood biomarkers associated with acute kidney injury (AKI) in patients newly diagnosed with multiple myeloma and being treated with Daratumumab SC. The aims of the study are: To measure changes in plasma and urinary biomarkers of AKI before initiation of Daratumumab therapy and 30 days after initiation of therapy. To establish whether these biomarkers serve to aid in early detection and prevention of AKI... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Acute Kidney Injury, Multiple Myeloma, Light Chain Nephropathy
Register for Updates
Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - a Randomized Clinical Trial in Acute Kidney Injury
NCT05758077
Recruiting
This randomized, controlled, pivotal study is intended to determine whether up to ten sequential 24-hour treatments with the Selective Cytopheretic Device (SCD) will improve survival in patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) when compared to CKRT alone (standard of care). This study is further intended to determine whether SCD therapy will reduce the duration of maintenance dialysis secondary to AKI. This study will enroll approximately 200... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Alabama Birmingham Hospital, Birmingham, Alabama +29 locations
Conditions: Acute Kidney Injury
Register for Updates
Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial
NCT04982419
Recruiting
This is a prospective, double-blind, sham-controlled, multicenter, randomized clinical trial is to study the effects of remote ischemic preconditioning on contrast-associated acute kidney injury, functional capacity, and major adverse kidney events in in patients with congestive heart failure undergoing cardiac catheterization and/or percutaneous coronary intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/27/2024
Locations: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania +2 locations
Conditions: Acute Kidney Injury, Heart Failure, Contrast Induced Nephropathy, Coronary Angiography, Percutaneous Coronary Intervention
Register for Updates
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
NCT05805709
Recruiting
The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +8 locations
Conditions: Acute Kidney Injury
Register for Updates
Optimizing Pulsatility During Cardiopulmonary Bypass
NCT05344573
Recruiting
Cardiopulmonary bypass during cardiac surgery provides blood flow to the body during surgery but has adverse effects on different organs. Blood flow during cardiopulmonary bypass may be pulsatile or non-pulsatile, which may impact normal organ function after surgery. The study will collect data on the type of cardiopulmonary bypass used during surgery and organ function to determine if there is an association between the type of bypass and organ function.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
11/18/2024
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Endothelial Dysfunction, Acute Kidney Injury
Register for Updates
Melatonin for Prevention of Kidney Injury
NCT05084196
Recruiting
This study will evaluate the safety and effectiveness of melatonin for the prevention of antibiotic associated acute kidney injury in hospitalized patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/30/2024
Locations: Robert Wood Johnson University Hospital, New Brunswick, New Jersey +1 locations
Conditions: Acute Kidney Injury, Adverse Drug Event
Register for Updates
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
NCT06150742
Recruiting
A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
10/10/2024
Locations: Wake Forest, Winston-Salem, North Carolina
Conditions: Acute Kidney Injury
Register for Updates
The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I
NCT04898010
Recruiting
This research study is being done to learn what effect 7 days of treatment with the Selective Cytopheretic Device (SCD) will have on these white blood cells in the bloodstream of patients with hepatorenal syndrome and to learn whether it has any effect on the blood circulation and kidney function.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/25/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Acute Kidney Injury, Hepatorenal Syndrome
Register for Updates
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
NCT06531642
Recruiting
The investigators propose a single-center, randomized, controlled trial to determine whether early initiation of proton pump inhibitor (PPI), pantoprazole, will decrease acute kidney injury (AKI) for trauma patients presenting with hemorrhagic shock compared to routine timing of initiation of PPI. Kidney injury will be assessed by the urinary kidney injury biomarkers, and the incidence, severity and AKI-free days within first week and major adverse kidney events (MAKE) at day 30. The specific ai... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2024
Locations: Memorial Hermann Texas Medical Center, Houston, Texas
Conditions: Acute Kidney Injury
Register for Updates